Semaglutide

Investigated uses

• Type 2 diabetes, chronic weight management, cardiovascular-risk reduction and MASH in label-defined populations; numerous additional trials exist.

Mechanism and hypotheses

• Semaglutide is a GLP-1 receptor agonist. In labeled products it increases glucose-dependent insulin secretion, reduces inappropriate glucagon secretion, delays gastric emptying early in treatment, and reduces calorie intake.
• Hypothesized: Any additional benefit or risk attributed to a gray-market powder, a nonlabeled route, or an unverified salt/form is unestablished.

Human evidence

• In STEP 1, 1,961 adults without diabetes were randomized for 68 weeks; semaglutide 2.4 mg weekly plus lifestyle intervention produced substantially greater mean weight loss than placebo. Limitations: Sponsor-funded obesity trial; results apply to the studied labeled injection and population, not gray powder.
• In SELECT, 17,604 adults with overweight/obesity and established cardiovascular disease but no diabetes had a lower incidence of major cardiovascular events with semaglutide than placebo. Limitations: Event-driven trial in a high-risk population; does not validate nonapproved formulations.

Safety highlights

• Nausea, vomiting, diarrhea, abdominal pain and constipation are common labeled adverse reactions.
• Label risks include pancreatitis, gallbladder disease, dehydration-associated acute kidney injury, severe gastrointestinal reactions, hypoglycemia with insulin/secretagogues and diabetic-retinopathy complications in susceptible patients.

Regulatory context

Approved semaglutide products exist, but FDA states that unapproved or research-only versions are not FDA-reviewed for safety, effectiveness or quality.